Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
-
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
-
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Summer is upon us, and it’s the perfect time to soak up the sun, embrace new adventures, and create lasting memories. Meaghan B Murphy, author of Your...
-
Austin, TX, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Adventure Tourism Market Size, Trends and Insights By Type (Hard Adventure, Soft...
-
SAYREVILLE, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Sabert Corporation, a leading global manufacturer of innovative food packaging, announces the launch of the groundbreaking Twist & Crispy™...
-
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
-
Atari announces it is reviving Infogrames as a publishing label, starting with purchase of Totally Reliable Delivery Services from tinyBuild LLC.
-
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
-
TransCode Therapeutics Reports 2023 Results; Provides Business Update
-
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer